2016 Fiscal Year Final Research Report
Development of the new therapeutic approach targeting IL-13Ralpha2 in pancreatic ductal adenocarcinoma.
| Project/Area Number |
25870846
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
Gastroenterology
|
|---|
| Research Institution | Juntendo University (2016)
Tokyo Health Care University (2013-2015) |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
NAKAJIMA Atsushi 横浜市立大学, 医学部, 教授
PURI Raj, K US Food and Drug Administration, Center for Biologics Evluation and Research Organization, Department director
|
|---|
| Project Period (FY) |
2013-04-01 – 2017-03-31
|
| Keywords | IL-13Ralpha2 / 膵臓癌 / 浸潤 / 転移 / 生命予後 / ポリフェノール / 神経浸潤 / HAT阻害薬 |
|---|
| Outline of Final Research Achievements |
We examined the relationship between the expression of IL-13Ralpha2 and survival time using the surgically resected samples of pancreatic cancer. Totally, 236 samples were examined, and they indicated that IL-13Ralpha2-high expresser showed significantly short survival time. Furthermore, IL-13Ralpha2 could enhance invasion to the nerve, because the expression of IL-13Ralpha2 showed strong correlation with the perineural invasion.
Then, we examined the cancer therapy targeting IL-13Ralpha2. Epigallocatechin gallate (EGCG) included in the green tea suppressed the expression of IL-13Ralpha2 in the pancreatic cancer cells. Orally administered ECGC extended the survival time of the host in the model mouse of pancreatic cancer.
|
| Free Research Field |
胆膵癌の治療
|
